Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial
Purpose: We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma (MM). Patients and Methods: In all, 827 eligible patients with newly diagnosed symptomatic MM were randomly assigned to receive induction therapy with vincristine, doxor...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 16, 2012
|
| In: |
Journal of clinical oncology
Year: 2012, Jahrgang: 30, Heft: 24, Pages: 2946-2955 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2011.39.6820 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1200/JCO.2011.39.6820 Verlag, Volltext: http://ascopubs.org/doi/10.1200/JCO.2011.39.6820 
|
| Verfasserangaben: | Pieter Sonneveld, Ingo G.H. Schmidt-Wolf, Bronno van der Holt, Laila el Jarari, Uta Bertsch, Hans Salwender, Sonja Zweegman, Edo Vellenga, Annemiek Broyl, Igor W. Blau, Katja C. Weisel, Shulamiet Wittebol, Gerard M.J. Bos, Marian Stevens-Kroef, Christof Scheid, Michael Pfreundschuh, Dirk Hose, Anna Jauch, Helgi van der Velde, Reinier Raymakers, Martijn R. Schaafsma, Marie-Jose Kersten, Marinus van Marwijk-Kooy, Ulrich Duehrsen, Walter Lindemann, Pierre W. Wijermans, Henk M. Lokhorst, and Hartmut M. Goldschmidt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1578101549 | ||
| 003 | DE-627 | ||
| 005 | 20220814203849.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180731s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2011.39.6820 |2 doi | |
| 035 | |a (DE-627)1578101549 | ||
| 035 | |a (DE-576)508101549 | ||
| 035 | |a (DE-599)BSZ508101549 | ||
| 035 | |a (OCoLC)1341015632 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Sonneveld, Pieter |d 1951- |e VerfasserIn |0 (DE-588)114640378X |0 (DE-627)100791730X |0 (DE-576)186122195 |4 aut | |
| 245 | 1 | 0 | |a Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma |b results of the randomized phase III HOVON-65/ GMMG-HD4 trial |c Pieter Sonneveld, Ingo G.H. Schmidt-Wolf, Bronno van der Holt, Laila el Jarari, Uta Bertsch, Hans Salwender, Sonja Zweegman, Edo Vellenga, Annemiek Broyl, Igor W. Blau, Katja C. Weisel, Shulamiet Wittebol, Gerard M.J. Bos, Marian Stevens-Kroef, Christof Scheid, Michael Pfreundschuh, Dirk Hose, Anna Jauch, Helgi van der Velde, Reinier Raymakers, Martijn R. Schaafsma, Marie-Jose Kersten, Marinus van Marwijk-Kooy, Ulrich Duehrsen, Walter Lindemann, Pierre W. Wijermans, Henk M. Lokhorst, and Hartmut M. Goldschmidt |
| 264 | 1 | |c July 16, 2012 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published ahead of print at July 16, 2012 | ||
| 500 | |a Gesehen am 31.07.2018 | ||
| 520 | |a Purpose: We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma (MM). Patients and Methods: In all, 827 eligible patients with newly diagnosed symptomatic MM were randomly assigned to receive induction therapy with vincristine, doxorubicin, and dexamethasone (VAD) or bortezomib, doxorubicin, and dexamethasone (PAD) followed by high-dose melphalan and autologous stem-cell transplantation. Maintenance consisted of thalidomide 50 mg (VAD) once per day or bortezomib 1.3 mg/m2 (PAD) once every 2 weeks for 2 years. The primary analysis was progression-free survival (PFS) adjusted for International Staging System (ISS) stage. Results: Complete response (CR), including near CR, was superior after PAD induction (15% v 31%; P < .001) and bortezomib maintenance (34% v 49%; P < .001). After a median follow-up of 41 months, PFS was superior in the PAD arm (median of 28 months v 35 months; hazard ratio [HR], 0.75; 95% CI, 0.62 to 0.90; P = .002). In multivariate analysis, overall survival (OS) was better in the PAD arm (HR, 0.77; 95% CI, 0.60 to 1.00; P = .049). In high-risk patients presenting with increased creatinine more than 2 mg/dL, bortezomib significantly improved PFS from a median of 13 months to 30 months (HR, 0.45; 95% CI, 0.26 to 0.78; P = .004) and OS from a median of 21 months to 54 months (HR, 0.33; 95% CI, 0.16 to 0.65; P < .001). A benefit was also observed in patients with deletion 17p13 (median PFS, 12 v 22 months; HR, 0.47; 95% CI, 0.26 to 0.86; P = .01; median OS, 24 months v not reached at 54 months; HR, 0.36; 95% CI, 0.18 to 0.74; P = .003). Conclusion: Bortezomib during induction and maintenance improves CR and achieves superior PFS and OS. | ||
| 700 | 1 | |a Bertsch, Uta |e VerfasserIn |0 (DE-588)1026849861 |0 (DE-627)727494163 |0 (DE-576)372176224 |4 aut | |
| 700 | 1 | |a Hose, Dirk |d 1969- |e VerfasserIn |0 (DE-588)139824995 |0 (DE-627)613790308 |0 (DE-576)313431698 |4 aut | |
| 700 | 1 | |a Jauch, Anna |d 1959- |e VerfasserIn |0 (DE-588)1025525140 |0 (DE-627)722525362 |0 (DE-576)168357496 |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 30(2012), 24, Seite 2946-2955 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma results of the randomized phase III HOVON-65/ GMMG-HD4 trial |
| 773 | 1 | 8 | |g volume:30 |g year:2012 |g number:24 |g pages:2946-2955 |g extent:10 |a Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma results of the randomized phase III HOVON-65/ GMMG-HD4 trial |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |t Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma |d 2012 |w (DE-627)1442175052 |w (DE-576)372175058 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.2011.39.6820 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://ascopubs.org/doi/10.1200/JCO.2011.39.6820 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180731 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 28 |y j | ||
| 998 | |g 1025525140 |a Jauch, Anna |m 1025525140:Jauch, Anna |d 910000 |d 910100 |e 910000PJ1025525140 |e 910100PJ1025525140 |k 0/910000/ |k 1/910000/910100/ |p 18 | ||
| 998 | |g 139824995 |a Hose, Dirk |m 139824995:Hose, Dirk |d 910000 |d 910100 |e 910000PH139824995 |e 910100PH139824995 |k 0/910000/ |k 1/910000/910100/ |p 17 | ||
| 998 | |g 1026849861 |a Bertsch, Uta |m 1026849861:Bertsch, Uta |d 910000 |d 910100 |e 910000PB1026849861 |e 910100PB1026849861 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 999 | |a KXP-PPN1578101549 |e 3019800668 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"relHost":[{"pubHistory":["1.1983 -"],"id":{"issn":["1527-7755"],"eki":["313116962"],"zdb":["2005181-5"]},"recId":"313116962","titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"title":[{"title_sort":"Journal of clinical oncology","title":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"issue":"24","year":"2012","pages":"2946-2955","volume":"30","extent":"10","text":"30(2012), 24, Seite 2946-2955"},"origin":[{"dateIssuedDisp":"1983-","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedKey":"1983"}],"corporate":[{"display":"American Society of Clinical Oncology","roleDisplay":"Herausgebendes Organ","role":"isb"}],"disp":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma results of the randomized phase III HOVON-65/ GMMG-HD4 trialJournal of clinical oncology","language":["eng"],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"10 S."}],"note":["Published ahead of print at July 16, 2012","Gesehen am 31.07.2018"],"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"July 16, 2012"}],"title":[{"title_sort":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma","title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma","subtitle":"results of the randomized phase III HOVON-65/ GMMG-HD4 trial"}],"person":[{"role":"aut","given":"Pieter","roleDisplay":"VerfasserIn","display":"Sonneveld, Pieter","family":"Sonneveld"},{"family":"Bertsch","given":"Uta","roleDisplay":"VerfasserIn","display":"Bertsch, Uta","role":"aut"},{"role":"aut","family":"Hose","roleDisplay":"VerfasserIn","given":"Dirk","display":"Hose, Dirk"},{"display":"Jauch, Anna","roleDisplay":"VerfasserIn","given":"Anna","family":"Jauch","role":"aut"},{"role":"aut","display":"Goldschmidt, Hartmut","roleDisplay":"VerfasserIn","given":"Hartmut","family":"Goldschmidt"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Pieter Sonneveld, Ingo G.H. Schmidt-Wolf, Bronno van der Holt, Laila el Jarari, Uta Bertsch, Hans Salwender, Sonja Zweegman, Edo Vellenga, Annemiek Broyl, Igor W. Blau, Katja C. Weisel, Shulamiet Wittebol, Gerard M.J. Bos, Marian Stevens-Kroef, Christof Scheid, Michael Pfreundschuh, Dirk Hose, Anna Jauch, Helgi van der Velde, Reinier Raymakers, Martijn R. Schaafsma, Marie-Jose Kersten, Marinus van Marwijk-Kooy, Ulrich Duehrsen, Walter Lindemann, Pierre W. Wijermans, Henk M. Lokhorst, and Hartmut M. Goldschmidt"]},"recId":"1578101549","id":{"doi":["10.1200/JCO.2011.39.6820"],"eki":["1578101549"]}} | ||
| SRT | |a SONNEVELDPBORTEZOMIB1620 | ||